MedTrace Logo

Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?

NCT04080505 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

The purpose of this research is to find out if SSKI (Potassium Iodide) reduces vascularity (the number and concentration of blood vessels) and improves how well patients do after surgery for removal of their whole thyroid gland in Graves' disease (an autoimmune disease that is a common cause of hyperthyroidism).

Conditions

  • Graves Disease

Interventions

DRUG

SSKI- Potassium Iodide

1g/mL, 2 drops orally 3 times a day for 7 days before surgery

Sponsors & Collaborators

Principal Investigators

  • Jennifer Kuo, MD · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-10
Primary Completion
2023-03-03
Completion
2023-03-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04080505 on ClinicalTrials.gov